| INTRODUCTION
There have been major advances in molecular pathological techniques in the last few years, particularly with the introduction of next-generation sequencing (NGS) for DNA and RNA. 1 Knowledge of the pathology of thyroid tumours has also evolved. Molecular diagnosis can be used for differential diagnosis, patient prognostication and as a marker for targeted therapy. This review concentrates on the use of molecular methods for diagnosis and prognostication.
The molecular pathology of thyroid tumours is now comparatively well understood. 2, 3 Thyroid tumours are thought to arise as a result of multiple mutational events ( Figures 1 and 2 , Table 1 ). Although thyroid nodules are extremely common, most thyroid nodules are benign. The risk of thyroid malignancy in any given thyroid nodule depends on the patient's age, genetics and previous history including radiation exposure. Metastatic tumours of the thyroid gland are also important as these are identified in 1.4%-3.0% of suspected thyroid cancer patients. eg BRAF V600E and TERT promoter, or PIK3CA, AKT1 and TP53 mutations in addition to BRAF V600E mutation alone predict adverse prognosis. [5] [6] [7] [8] Of interest to cytology is that the aggressive variants of PTC, as well as showing cytological and histological differences to classical PTC, also show differing molecular profiles ( Figure 1 and Table 1 ).
Tall cell variant of PTC shows higher frequency (up to 90% for BRAF V600E and TERT promoter 31%) mutation compared to much lower rates seen in conventional PTC. 9, 10 Columnar cell variant of PTC is rare. BRAF V600E mutations are found in one-third of these tumours. 11 In hobnail variant PTC, BRAF V600E mutations are identified in a high percentage of cases; 12,13 one study showed a 94.1% rate of BRAF V600E mutation. 14 In diffuse sclerosing variant, which is uncommon and typically affects younger patients, RET/PTC rearrangements are found in a high percentage of cases while BRAF V600E mutations are rare in the range of 0%-61%, although most studies suggest zero or very low rates of BRAF V600E mutation.
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ALK translocations are said to be more common in diffuse sclerosing variant PTC, seen in one series in three of 14 ALK translocated PTC cancer cases, although ALK fusions did not predict more aggressive tumour behaviour. 16 Solid variant of PTC is a rare variant defined by a solid/trabecular growth pattern. Foci of solid variant PTC were identified in papillary carcinomas in a small cohort of Chernobyl patients exposed to ionising radiation and were associated with RET/PTC3 or ETV6/NTRK3 rearrangements. 17 As the newly described mammary analogue secretory carcinoma (MASC) of the thyroid characteristically shows ETV6/NTRK3 fusion it has been suggested that some ETV6/NTRK3 fusion solid type PTC might be related to MASC tumours. 18 PTEN point mutations or small deletions in 5%-10% and PIK3CA point mutations in 5%-10%. 23 The oncocytic (also known as H€ urthle cell) subtype of follicular carcinoma shows a much lower frequency of RAS point mutations (10%-15%) and PAX8/PPARG rearrangements (0%-5%) and absence of PIK3CA and PTEN point mutations. ThyroSeq v2 was initially validated in a single institutional combined retrospective and prospective study of 143 Bethesda category IV thyroid nodules 40 with a specificity of 93%, sensitivity of 90%, PPV of 83% and NPV of 96%. 40 In a follow-up, single-institution, prospective study of 465 Bethesda category III thyroid nodules a sensitivity of 90.9%, specificity of 92.1%, PPV of 76.9% and NPV of 97.2% was seen. 41 Using a comprehensive NGS panel such as ThyroSeq v2 identification of RAS or a RAS-like mutation implies a high probability (~80%) of either a low-risk cancer or NIFTP for which surgery can often be limited to thyroid lobectomy. Test positivity for an isolated BRAF V600E or other BRAF V600E-like mutation implies a very high (>99%) probability of cancer, expected to be of intermediate risk for disease recurrence. These patients may undergo total thyroidectomy or lobectomy, depending on the clinical situation. ThyroSeq v2 positivity for multiple mutations or highrisk mutations such as TERT is virtually diagnostic of cancer and increased risk of disease recurrence and possibly cancer-related mortality so these patients can benefit from total thyroidectomy. 
| Practical applications

